APA aipamena

Lee, M., Chung, W., Lee, J., Park, C., Park, W., Song, B., & Youn, H. (2021). Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med.

Chicago Style aipamena

Lee, Myunhee, Woo‐Baek Chung, Ji‐eun Lee, Chan‐Seok Park, Woo‐Chan Park, Byung‐Joo Song, and Ho‐Joong Youn. "Candesartan and Carvedilol for Primary Prevention of Subclinical Cardiotoxicity in Breast Cancer Patients Without a Cardiovascular Risk Treated With Doxorubicin." Cancer Med 2021.

MLA aipamena

Lee, Myunhee, et al. "Candesartan and Carvedilol for Primary Prevention of Subclinical Cardiotoxicity in Breast Cancer Patients Without a Cardiovascular Risk Treated With Doxorubicin." Cancer Med 2021.